Eli Lilly and Company (ETR:LLY)

Market Cap	608.32B
Revenue (ttm)	45.34B
Net Income (ttm)	10.28B
Shares Out	n/a
EPS (ttm)	11.37
PE Ratio	59.20
Forward PE	30.81
Dividend	5.18 (0.77%)
Ex-Dividend Date	May 16, 2025

Volume	3,283
Average Volume	3,446
Open	679.20
Previous Close	677.00
Day's Range	676.90 - 698.80
52-Week Range	604.60 - 888.30
Beta	0.39
RSI	52.62
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD